Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 90 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 1781

Topic: Biology, Genetics & Bone Healing

A 45-year-old patient undergoes an open reduction and internal fixation of a diaphyseal forearm fracture using absolute stability techniques (lag screw and neutralization plate). Which type of bone healing is expected, and what is the primary biological mediator initiating this process?

. Secondary bone healing mediated by endochondral ossification
. Primary bone healing mediated by cutting cones (osteoclasts followed by osteoblasts)
. Intramembranous ossification with robust callus formation
. Contact healing mediated exclusively by chondrocyte hypertrophy
. Gap healing characterized by immediate woven bone formation and subsequent remodeling

Correct Answer & Explanation

. Primary bone healing mediated by cutting cones (osteoclasts followed by osteoblasts)

Explanation

Absolute stability (rigid fixation with absolute lack of interfragmentary strain) leads to primary bone healing. This process bypasses the inflammatory phase and callus formation entirely. Contact healing occurs directly via 'cutting cones,' which consist of a leading edge of osteoclasts that resorb a channel across the fracture line, followed immediately by osteoblasts that deposit lamellar bone in a Haversian remodeling pattern.

Question 1782

Topic: Biology, Genetics & Bone Healing

Aseptic loosening is the most common cause of late failure in total joint arthroplasty. The biological cascade leading to periprosthetic osteolysis is primarily initiated by the phagocytosis of wear debris. Which cell type is the principal driver of this initial inflammatory response, and what is the primary cytokine released?

. Osteoblast; Interleukin-10
. T-lymphocyte; Interferon-gamma
. Macrophage; Tumor Necrosis Factor-alpha (TNF-alpha)
. Osteoclast; Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)
. Fibroblast; Transforming Growth Factor-beta (TGF-beta)

Correct Answer & Explanation

. Macrophage; Tumor Necrosis Factor-alpha (TNF-alpha)

Explanation

The initiation of periprosthetic osteolysis occurs when tissue macrophages phagocytose particulate wear debris (typically polyethylene, but also metal or cement). Once activated, macrophages release a cascade of pro-inflammatory cytokines, most notably TNF-alpha, IL-1, and IL-6. These cytokines subsequently stimulate osteoblast expression of RANKL, which activates osteoclasts, leading to active bone resorption and subsequent aseptic loosening.

Question 1783

Topic: Biology, Genetics & Bone Healing

A patient is diagnosed with familial hypophosphatemic rickets (X-linked dominant). The underlying pathophysiology involves an overproduction of Fibroblast Growth Factor 23 (FGF23). What is the primary renal effect of excessive FGF23 in this condition?

. Increased reabsorption of calcium in the distal convoluted tubule
. Decreased reabsorption of phosphate in the proximal tubule and decreased 1-alpha-hydroxylase activity
. Increased reabsorption of phosphate in the distal tubule and increased 1-alpha-hydroxylase activity
. Decreased reabsorption of calcium in the loop of Henle
. Increased secretion of parathyroid hormone from the parathyroid gland

Correct Answer & Explanation

. Decreased reabsorption of phosphate in the proximal tubule and decreased 1-alpha-hydroxylase activity

Explanation

FGF23 is a phosphatonin primarily secreted by osteocytes. It acts directly on the kidneys to downregulate the sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc) in the proximal tubule, leading to pronounced renal phosphate wasting. Additionally, FGF23 strongly inhibits the enzyme 1-alpha-hydroxylase, decreasing the synthesis of active 1,25-dihydroxyvitamin D. In familial hypophosphatemic rickets (due to PHEX gene mutations), elevated FGF23 leads to severe hypophosphatemia and paradoxically normal or low calcitriol levels.

Question 1784

Topic: Biology, Genetics & Bone Healing

A 65-year-old man with a long-standing history of bone pain, increasing head size, and hearing loss presents with a subtrochanteric femur fracture after a minor fall. What is the characteristic histologic finding of the abnormal bone at the fracture site?

. Prominent cement lines with a mosaic pattern of lamellar bone
. Sheets of atypical plasma cells with eccentric nuclei
. Woven bone lacking osteoblastic rimming
. Multinucleated giant cells in a background of mononuclear stromal cells
. Nests of cartilage with prominent binucleate chondrocytes

Correct Answer & Explanation

. Prominent cement lines with a mosaic pattern of lamellar bone

Explanation

The clinical presentation is classic for Paget's disease of bone (osteitis deformans), which is characterized by increased, disorganized bone turnover. The hallmark histologic finding is a 'mosaic' pattern of lamellar bone with prominent, haphazardly arranged cement lines, reflecting repeated, chaotic episodes of bone resorption by overactive osteoclasts and subsequent rapid formation by osteoblasts.

Question 1785

Topic: Biology, Genetics & Bone Healing

A 55-year-old woman with metastatic breast cancer to the spine and pelvis is prescribed an agent to reduce the incidence of skeletal-related events (pathologic fractures, spinal cord compression). The prescribed agent is a fully human monoclonal antibody. What is its specific mechanism of action?

. Inhibits farnesyl pyrophosphate synthase in the mevalonate pathway
. Binds to RANK ligand, preventing its interaction with RANK
. Directly induces apoptosis of circulating osteoclasts
. Antagonizes the parathyroid hormone receptor on osteoblasts
. Inhibits the Wnt/beta-catenin signaling pathway

Correct Answer & Explanation

. Binds to RANK ligand, preventing its interaction with RANK

Explanation

Denosumab is a fully human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand). By binding RANKL, it prevents it from interacting with its receptor, RANK, on the surface of osteoclasts and their precursors. This inhibition suppresses osteoclast formation, function, and survival, thereby reducing bone resorption. Bisphosphonates, on the other hand, inhibit farnesyl pyrophosphate synthase.

Question 1786

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with worsening knee pain. Radiographs reveal an eccentric, purely lytic lesion in the distal femoral epiphysis extending to the subchondral bone without a sclerotic rim. Biopsy confirms Giant Cell Tumor of bone (GCT). Which of the following accurately describes the molecular pathogenesis and targeted therapy for this tumor?

. The multinucleated giant cells express RANKL; Denosumab is indicated for unresectable tumors
. The mononuclear stromal cells express RANKL; Denosumab is indicated for unresectable tumors
. The mononuclear stromal cells express RANK; Bisphosphonates are the primary targeted therapy
. The giant cells express RANK; Imatinib is the primary targeted therapy
. The tumor is driven by an EWS-FLI1 mutation; targeted chemotherapy is required

Correct Answer & Explanation

. The mononuclear stromal cells express RANKL; Denosumab is indicated for unresectable tumors

Explanation

In Giant Cell Tumor of bone (GCT), the true neoplastic cells are the mononuclear spindle-like stromal cells. These cells express high levels of RANKL. The characteristic multinucleated giant cells are actually non-neoplastic, reactive osteoclast-like cells that express the RANK receptor. Denosumab, a RANKL inhibitor, binds the RANKL produced by the stromal cells, depriving the giant cells of the signal needed to survive and cause osteolysis. It is FDA-approved for locally advanced or unresectable GCTs.

Question 1787

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a lytic lesion in the distal femur extending to the subchondral bone. Biopsy confirms the diagnosis of a giant cell tumor of bone. She is treated with denosumab preoperatively to downstage the tumor. What is the mechanism of action of this medication?

. Binds to the RANK receptor to prevent activation
. Binds to RANKL to prevent its interaction with the RANK receptor
. Inhibits matrix metalloproteinases in the tumor microenvironment
. Competitively inhibits the osteoclast proton pump
. Stimulates osteoprotegerin (OPG) production by osteoblasts

Correct Answer & Explanation

. Binds to RANKL to prevent its interaction with the RANK receptor

Explanation

Denosumab is a fully human monoclonal antibody that specifically binds to Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). By binding to RANKL, it prevents RANKL from interacting with the RANK receptor located on the surface of osteoclasts and osteoclast precursors. This inhibits osteoclast formation, function, and survival. In giant cell tumors, the neoplastic stromal cells express high levels of RANKL, which recruits and activates the reactive multinucleated giant cells that cause bone destruction.

Question 1788

Topic: Biology, Genetics & Bone Healing
During secondary fracture healing, the soft callus is gradually replaced by hard callus through the process of endochondral ossification. Which of the following collagen types is most highly expressed by hypertrophic chondrocytes as the cartilage matrix calcifies before being replaced by woven bone?
. Type I collagen
. Type II collagen
. Type III collagen
. Type IX collagen
. Type X collagen

Correct Answer & Explanation

. Type X collagen

Explanation

Type X collagen is uniquely synthesized by hypertrophic chondrocytes during endochondral ossification and in the growth plate. It is considered a specific marker of chondrocyte hypertrophy and plays a critical role in the calcification of the cartilage matrix, facilitating subsequent vascular invasion and osteoblast-mediated deposition of Type I collagen (bone).

Question 1789

Topic: Biology, Genetics & Bone Healing

A 72-year-old woman with severe osteoporosis and a history of a vertebral compression fracture is started on daily subcutaneous injections of teriparatide. Which of the following best describes the physiological effect of this specific dosing regimen?

. It inhibits the ruffled border formation of mature osteoclasts.
. It acts as a selective antagonist at estrogen receptors in bone.
. It preferentially stimulates osteoblastic bone formation over bone resorption.
. It cross-links collagen fibers to directly increase bone toughness.
. It induces early apoptosis of functional osteoclasts.

Correct Answer & Explanation

. It preferentially stimulates osteoblastic bone formation over bone resorption.

Explanation

Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). While continuous endogenous elevation of PTH (as in hyperparathyroidism) leads to net bone resorption, intermittent (daily) exogenous administration of PTH analogs like teriparatide exerts an anabolic effect. It preferentially stimulates osteoblast activity and lifespan over osteoclast activity, leading to a net increase in new bone formation.

Question 1790

Topic: Biology, Genetics & Bone Healing

A 60-year-old man with metastatic prostate cancer to the spine is treated with intravenous zoledronic acid to reduce the risk of skeletal-related events. Nitrogen-containing bisphosphonates like zoledronic acid inhibit osteoclast function primarily by interfering with which of the following intracellular pathways?

. Wnt/beta-catenin signaling pathway
. Mevalonate pathway
. RANKL/RANK signaling pathway
. Glycolysis pathway
. Cytochrome P450 pathway

Correct Answer & Explanation

. Mevalonate pathway

Explanation

Nitrogen-containing bisphosphonates (e.g., zoledronic acid, alendronate) inhibit farnesyl pyrophosphate (FPP) synthase, a key enzyme in the mevalonate pathway. This prevents the prenylation of small GTP-binding proteins (such as Ras, Rho, and Rac) that are essential for osteoclast function, formation of the ruffled border, and cell survival, ultimately leading to osteoclast apoptosis. Non-nitrogen-containing bisphosphonates (e.g., etidronate) act differently, by being incorporated into toxic ATP analogs.

Question 1791

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) induce bone formation primarily by signaling through which of the following intracellular pathways?

. Wnt/beta-catenin
. RANK/RANKL
. Smad 1/5/8
. JAK/STAT
. MAP kinase

Correct Answer & Explanation

. Smad 1/5/8

Explanation

BMPs are members of the TGF-beta superfamily. They bind to serine/threonine kinase receptors on the cell surface, which then phosphorylate intracellular Smad proteins (specifically Smad 1, 5, and 8). These phosphorylated Smads form a complex with Smad 4, translocate to the nucleus, and regulate the transcription of osteogenic genes such as Runx2.

Question 1792

Topic: Biology, Genetics & Bone Healing

Denosumab is utilized in the management of giant cell tumor of bone and metastatic bone disease. It achieves its therapeutic effect by directly binding to and inhibiting which of the following?

. RANK receptor on osteoclasts
. RANKL produced by osteoblasts and stromal cells
. Osteoprotegerin (OPG)
. Macrophage colony-stimulating factor (M-CSF)
. Cathepsin K

Correct Answer & Explanation

. RANKL produced by osteoblasts and stromal cells

Explanation

Denosumab is a fully human monoclonal antibody that binds to Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL), a protein produced by osteoblasts, stromal cells, and neoplastic cells (such as the stromal cells in giant cell tumor of bone). By binding to RANKL, denosumab prevents RANKL from binding to the RANK receptor on osteoclasts and osteoclast precursors, thereby inhibiting osteoclast formation, function, and survival.

Question 1793

Topic: Biology, Genetics & Bone Healing

A 28-year-old woman is diagnosed with a recurrent giant cell tumor of the proximal tibia after previous curettage and cementation. Her surgeon recommends systemic therapy with denosumab to downstage the tumor prior to a second procedure. What is the mechanism of action of this medication in the context of this lesion?

. It directly induces apoptosis of the neoplastic mononuclear stromal cells.
. It binds to RANKL, preventing the activation and recruitment of osteoclast-like giant cells.
. It acts as a bisphosphonate, inhibiting the mevalonate pathway in giant cells.
. It inhibits the vascular endothelial growth factor (VEGF) pathway.
. It blocks the PTH receptor on the surface of neoplastic cells.

Correct Answer & Explanation

. It binds to RANKL, preventing the activation and recruitment of osteoclast-like giant cells.

Explanation

Denosumab is a fully human monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL). In giant cell tumor of bone, the neoplastic cells are the mononuclear stromal cells, which express high levels of RANKL. This recruits and activates normal osteoclast-like giant cells that cause bone destruction. Denosumab blocks this interaction, leading to depletion of the giant cells and ossification of the tumor stroma.

Question 1794

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman has a recurrent giant cell tumor of the proximal tibia. She is started on denosumab prior to surgical intervention. What is the precise mechanism of action of this pharmacological agent?

. It induces apoptosis of the neoplastic mononuclear stromal cells directly.
. It binds to the RANK receptor on the osteoclast precursor, preventing activation.
. It binds to RANK ligand (RANKL), preventing its interaction with RANK.
. It inhibits the farnesyl pyrophosphate synthase enzyme in the mevalonate pathway.
. It binds to osteoprotegerin (OPG), preventing it from neutralizing RANKL.

Correct Answer & Explanation

. It binds to RANK ligand (RANKL), preventing its interaction with RANK.

Explanation

Denosumab is a fully human monoclonal antibody that binds directly to RANKL, preventing it from interacting with the RANK receptor on osteoclasts and their precursors. In Giant Cell Tumor of Bone (GCTB), the neoplastic cells are the mononuclear stromal cells, which express high levels of RANKL. The RANKL stimulates the non-neoplastic, multinucleated giant cells (osteoclast-like) to cause massive bone resorption. Denosumab stops this recruitment and activity. Bisphosphonates inhibit farnesyl pyrophosphate synthase.

Question 1795

Topic: Biology, Genetics & Bone Healing

A diaphyseal tibia fracture is treated with a well-fitted unlocked intramedullary nail. According to Perren's strain theory, what tissue will predominantly form in the fracture gap if the interfragmentary strain is maintained between 2% and 10%?

. Woven bone
. Lamellar bone
. Fibrocartilage
. Granulation tissue
. Dense fibrous connective tissue

Correct Answer & Explanation

. Fibrocartilage

Explanation

Perren's strain theory predicts the type of tissue that can survive and form in a fracture gap based on the deformation (strain). Granulation tissue can tolerate high strain (up to 100%). Fibrocartilage can tolerate strain up to about 10-15%. Woven bone can form when strain is less than 2%. Lamellar bone requires an even lower strain environment. Therefore, a strain environment between 2% and 10% will not permit direct bone formation but will allow the formation of fibrocartilage, characteristic of endochondral ossification during secondary fracture healing.

Question 1796

Topic: Biology, Genetics & Bone Healing

A 65-year-old woman with severe postmenopausal osteoporosis is treated with romosozumab. This medication primarily increases bone mineral density by neutralizing a protein that typically inhibits which of the following signaling pathways?

. Wnt/beta-catenin pathway
. RANK/RANKL pathway
. Notch signaling pathway
. TGF-beta/Smad pathway
. Hedgehog signaling pathway

Correct Answer & Explanation

. Wnt/beta-catenin pathway

Explanation

Romosozumab is a monoclonal antibody directed against Sclerostin. Sclerostin is a glycoprotein secreted by osteocytes that naturally inhibits bone formation by antagonizing the Wnt/beta-catenin signaling pathway in osteoblasts. By blocking Sclerostin, romosozumab uninhibits the Wnt pathway, leading to a profound anabolic (bone-forming) effect and a transient decrease in bone resorption, significantly increasing bone mineral density.

Question 1797

Topic: Biology, Genetics & Bone Healing

A 60-year-old man is diagnosed with multiple myeloma. He has diffuse osteolytic lesions in his axial skeleton. The osteolytic nature of these bone lesions is primarily driven by multiple myeloma cells secreting factors that heavily upregulate which of the following?

. Sclerostin
. Osteoprotegerin (OPG)
. RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
. Parathyroid hormone-related peptide (PTHrP)
. Bone morphogenetic protein 2 (BMP-2)

Correct Answer & Explanation

. RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)

Explanation

Multiple myeloma cells secrete various cytokines (e.g., MIP-1 alpha, IL-3, IL-6) that dramatically upregulate RANKL expression by bone marrow stromal cells and osteoblasts, while simultaneously downregulating OPG. This leads to massive osteoclast activation and the characteristic uncoupled, purely osteolytic lesions seen in myeloma. While PTHrP is a major mediator of osteolysis and hypercalcemia in metastatic carcinomas (like breast or lung), it is not the primary driver in multiple myeloma.

Question 1798

Topic: Biology, Genetics & Bone Healing

A surgeon uses a massive structural cortical allograft for intercalary reconstruction following a tumor resection. Over the subsequent years, the allograft undergoes the process of 'creeping substitution.' In a cortical allograft, which of the following accurately describes this physiological process?

. The graft is rapidly vascularized within weeks, leading to complete cellular repopulation by 6 months.
. Osteoclasts initially resorb the host-graft junction, followed by osteoblastic bone deposition, significantly weakening the graft temporarily.
. Osteoblasts form a woven bone scaffold over the existing dead trabeculae without prior resorption.
. The graft induces intense immunologic rejection, requiring lifelong immunosuppression.
. Mesenchymal stem cells in the allograft differentiate into osteoblasts to form new bone.

Correct Answer & Explanation

. Osteoclasts initially resorb the host-graft junction, followed by osteoblastic bone deposition, significantly weakening the graft temporarily.

Explanation

Creeping substitution in cortical grafts is characterized by initial osteoclastic resorption followed by osteoblastic bone formation via cutting cones. Because resorption precedes formation, structural cortical allografts become significantly mechanically weaker during the first 1 to 2 years after implantation before progressively gaining strength. Unlike cancellous grafts which are rapidly incorporated, cortical grafts are dense, revascularize slowly, and often remain partially necrotic in their core indefinitely.

Question 1799

Topic: Biology, Genetics & Bone Healing

A 72-year-old woman on oral alendronate for 10 years presents with a transverse, non-comminuted fracture of the femoral shaft with a medial cortical spike, following a minor trip and fall. She reported having lateral thigh pain for three months prior to the fall. The pathogenesis of her fracture is primarily related to which of the following mechanisms?

. Increased osteoblastic activity leading to brittle woven bone
. Suppression of targeted intracortical remodeling leading to accumulation of microdamage
. Direct toxicity to osteocytes causing widespread osteonecrosis
. Disruption of collagen cross-linking via inhibition of lysyl oxidase
. Excessive osteoclastic resorption leading to profound cortical thinning

Correct Answer & Explanation

. Suppression of targeted intracortical remodeling leading to accumulation of microdamage

Explanation

Atypical femur fractures (AFFs) are associated with prolonged bisphosphonate use. Bisphosphonates powerfully suppress osteoclast function, which severely limits the normal physiological process of targeted intracortical bone remodeling. Without remodeling, physiological microcracks accumulate, coalesce, and ultimately propagate, leading to a stress fracture that can complete into a displaced atypical fracture. Classic features include a transverse fracture, medial cortical spike, and lateral cortical thickening (beaking).

Question 1800

Topic: Biology, Genetics & Bone Healing

A 34-year-old woman presents with knee pain. Radiographs reveal an eccentric, lytic, epiphyseal lesion in the distal femur extending to the subchondral bone. Biopsy confirms multinucleated giant cells interspersed with mononuclear stromal cells. Which of the following targeted therapies acts by binding to RANKL, and what is its specific role in the medical management of this lesion?

. Denosumab; it induces apoptosis of the multinucleated giant cells directly.
. Denosumab; it inhibits osteoclastogenesis by binding RANKL, targeting the neoplastic mononuclear stromal cells' signaling pathway.
. Bisphosphonates; they competitively inhibit RANKL on the surface of giant cells.
. Imatinib; it inhibits the tyrosine kinase activity in the mononuclear cells.
. Denosumab; it inhibits RANK receptor directly on the multinucleated giant cells.

Correct Answer & Explanation

. Denosumab; it inhibits osteoclastogenesis by binding RANKL, targeting the neoplastic mononuclear stromal cells' signaling pathway.

Explanation

In Giant Cell Tumor of Bone (GCTB), the mononuclear stromal cells are the true neoplastic cells, and they express high levels of RANKL. The multinucleated giant cells are reactive osteoclast-like cells that express RANK. Denosumab is a monoclonal antibody that binds to RANKL, preventing its interaction with RANK and thereby inhibiting the recruitment and activation of the reactive bone-destroying giant cells.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page